X.S.R. is the recipient of a Banting & Best Diabetes Centre Fellowship in Diabetes Care (funded by Eli Lilly Canada).

GLP-1 (glucagon-like peptide-1) discovered in the 1980s functions as a hormone derived from the proglucagon sequence and was found to have a transformative impact on the treatment of diabetes and ...

Eli Lilly has ... generation of drugs that Lilly is looking to for growth in the coming years, alongside Alzheimer’s therapy donanemab, Mounjaro (tirzepatide) for diabetes and possibly obesity ...

Novo and competitors such as Sanofi and Eli Lilly were ... except the US and Canada. He says the potential for growth in these markets is enormous – global rates of type 2 diabetes now stand ...

Eli Lilly and Company (NYSE:LLY), a leading pharmaceutical giant with a market capitalization of $724 billion, has been ...

Eli Lilly's Ozempic-rivaling weight-loss pill orforglipron could be available in early 2026. Its retatrutide may be as ...

Novo Nordisk agreed to cap insulin prices to settle a lawsuit in which Minnesota's attorney general accused the three largest ...

Eli Lilly is experiencing explosive growth thanks to its diabetes and obesity treatments. Beyond weight loss, the company is quietly building a fast-growing oncology business. This is an enormous ...

agonists used to treat diabetes and help with chronic weight management. While Novo Nordisk's Ozempic is the most mainstream GLP-1 medication, Eli Lilly (NYSE: LLY) has two blockbuster weight loss ...

Edited excerpts from the interview: BT: Eli Lilly’s Mounjaro (tirzepatide) has garnered significant attention globally for its efficacy in managing obesity and type-2 diabetes. When can we ...